The use of alpha emitters as a therapeutic nuclide for cancer therapy becomes more interesting in the field of Nuclear Medicine. 213Bi (t1/2 = 45.6 min) is one of the most widely used alpha emitter. For receptor-mediated processes high specific activity (SA, expressed in MBq per mass ligand) is required, since the uptake is dependent on the amounts of receptors available on the tumor. However due to the radiochemical limitation; e.g. high osmolarity, large reaction volume, etc., applications to in vitro and in vivo for this processes, especially in a mouse model (<0.2 mL at 0.3 osmol in a 25 g mouse) are problematic and need adjustment.
Here we present optimized labeling conditions of 213Bi-DOTA-TATE for preclinical applications. Beside optimizing the conditions, the radiochemical purity (RCP) was monitored.
CHAN Ho-Sze;
DE BLOIS Erik;
KONIJNENBERG M.W.;
MORGENSTERN Alfred;
BRUCHERTSEIFER Frank;
BREEMAN Wouter;
DE JONG Marion;
2014-07-31
SOC NUCLEAR MEDICINE INC
JRC88669
0161-5505,
https://publications.jrc.ec.europa.eu/repository/handle/JRC88669,
| Name | Country | City | Type |
|---|
This document is only visible at the Commission level.
You are not authorized to publish or distribute it outside the European Commission.
This is a public document. You can share this publication.
Datasets
| ID | Title | Public URL |
|---|
Dataset collections
| ID | Acronym | Title | Public URL |
|---|
Scripts / source codes
| Description | Public URL |
|---|
Additional supporting files
| File name | Description | File type |
|---|